Sunitinib malateIZZEDINE, Hassane; BUHAESCU, Irina; RIXE, Olivier et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 3, pp 357-364, issn 0344-5704, 8 p.Article

Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiationPLASTARAS, John P; KIM, Seok-Hyun; DIEHL, J. Alan et al.Cancer research (Baltimore). 2007, Vol 67, Num 19, pp 9443-9454, issn 0008-5472, 12 p.Article

Dermatologic symptoms associated with the multikinase inhibitor sorafenibROBERT, Caroline; MATEUS, Christina; SPATZ, Alain et al.Journal of the American Academy of Dermatology. 2009, Vol 60, Num 2, pp 299-305, issn 0190-9622, 7 p.Article

A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor VandetanibGIACCHERO, Damien; RAMACCIOTTI, Constanza; ROBERT, Caroline et al.Archives of dermatology (1960). 2012, Vol 148, Num 12, pp 1418-1420, issn 0003-987X, 3 p.Article

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism StudiesYAP, Timothy A; ARKENAU, Hendrik-Tobias; LEACH, Martin O et al.Clinical cancer research (Print). 2013, Vol 19, Num 4, pp 909-919, issn 1078-0432, 11 p.Article

Profound Inhibition of Antigen-SpecificT-Cell Effector Functions by DasatinibWEICHSEL, Ralf; DIX, Carolin; EINSELE, Hermann et al.Clinical cancer research. 2008, Vol 14, Num 8, pp 2484-2491, issn 1078-0432, 8 p.Article

Sorafenib use while waiting for liver transplant: We still need to waitFINN, Richard S.Journal of hepatology. 2012, Vol 56, Num 3, pp 723-725, issn 0168-8278, 3 p.Article

Drug Therapy: SorafenibFINN, Richard S.Hepatology (Baltimore, Md.). 2010, Vol 51, Num 5, pp 1843-1849, issn 0270-9139, 7 p.Article

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptorBROWNLOW, N; MOL, C; HAYFORD, C et al.Leukemia. 2009, Vol 23, Num 3, pp 590-594, issn 0887-6924, 5 p.Article

Surrogate biomarkers in evaluating response to anti-angiogenic agents : focus on sunitinibDEPRIMO, S. E; BELLO, C.Annals of oncology. 2007, Vol 18, issn 0923-7534, x11-x19, SUP10Conference Paper

Sorafenib: Where Do We Go from Here?SIEGEL, Abby B; OLSEN, Sonja K; MAGUN, Arthur et al.Hepatology (Baltimore, Md.). 2010, Vol 52, Num 1, pp 360-369, issn 0270-9139, 10 p.Article

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. CommentaryJOENSUU, Heikki; CHU, Tammy F; DESAI, Jayesh et al.Lancet (British edition). 2007, Vol 370, Num 9604, issn 0140-6736, 1978-1980, 2011-2019 [12 p.]Article

Dasatinib enhances megakaryocyte differentiation but inhibits platelet formationMAZHARIAN, Alexandra; GHEVAERT, Cedric; LIN ZHANG et al.Blood. 2011, Vol 117, Num 19, pp 5198-5206, issn 0006-4971, 9 p.Article

Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor ReceptorsKRUSER, Tim J; WHEELER, Deric L; ARMSTRONG, Eric A et al.Clinical cancer research (Print). 2010, Vol 16, Num 14, pp 3639-3647, issn 1078-0432, 9 p.Article

Metabolism and Disposition of Dasatinib after Oral Administration to HumansCHRISTOPHER, Lisa J; DONGHUI CUI; GALBRAITH, Susan et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1357-1364, issn 0090-9556, 8 p.Article

New challenges in kidney cancer therapy : sunitinibIZZEDINE, H; BILLEMONT, B; THIBAULT, F et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, ix83-ix86, SUP9Conference Paper

Regorafenib: carving a niche in the crowded therapeutic landscapeSIROHI, Bhawna; DEEPA SUSAN PHILIP; SHRIKHANDE, Shailesh V et al.Expert review of anticancer therapy. 2013, Vol 13, Num 4, pp 385-393, issn 1473-7140, 9 p.Article

Dasatinib inhibits proinflammatory functions of mature human neutrophilsFUTOSI, Krisztina; NEMETH, Tamas; PICK, Robert et al.Blood. 2012, Vol 119, Num 21, pp 4981-4991, issn 0006-4971, 11 p.Article

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibLEE, W. J; LEE, J. L; CHANG, S. E et al.British journal of dermatology (1951). 2009, Vol 161, Num 5, pp 1045-1051, issn 0007-0963, 7 p.Article

Acute pancreatitis associated with sorafenibMINGQING LI; SRINIVAS, Sandy.Southern medical journal (Birmingham). 2007, Vol 100, Num 9, pp 909-911, issn 0038-4348, 3 p.Article

Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanibCASADO-VERRIER, B; PEREZ-SANTOS, S; DELGADO-MUCIENTES, C et al.British journal of dermatology (1951). 2014, Vol 171, Num 6, pp 1559-1561, issn 0007-0963, 3 p.Article

Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and MetastasisCHAN, Christine M; XIA JING; PIKE, Laura A et al.Clinical cancer research (Print). 2012, Vol 18, Num 13, pp 3580-3591, issn 1078-0432, 12 p.Article

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug ResistanceGOTINK, Kristy J; BROXTERMAN, Henk J; GRIFFIOEN, Arjan W et al.Clinical cancer research (Print). 2011, Vol 17, Num 23, pp 7337-7346, issn 1078-0432, 10 p.Article

Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppressionTAKEUCHI, Ario; SHIOTA, Masaki; TATSUGAMI, Katsunori et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1557-1564, issn 0344-5704, 8 p.Article

Lck is a key target of imatinib and dasatinib in T-cell activationLEE, K. C; OUWEHAND, I; GIANNINI, A. L et al.Leukemia. 2010, Vol 24, Num 4, pp 896-900, issn 0887-6924, 5 p.Article